Enzalutamide: a new prostate cancer targeted therapy against the androgen receptor
View/ Open
Use this link to cite
http://hdl.handle.net/2183/21551
Except where otherwise noted, this item's license is described as Atribución-NoComercial-SinDerivadas 3.0 España
Collections
- GI-FENM - Artigos [117]
Metadata
Show full item recordTitle
Enzalutamide: a new prostate cancer targeted therapy against the androgen receptorAuthor(s)
Date
2015-03Citation
Lázaro Quintela M, León Mateos L, Vázquez Estévez S, et al. Enzalutamide: a new prostate cancer targeted therapy against the androgen receptor. Cancer Treat Rev. 2015; 41(3):247-253
Abstract
[Abstract] Enzalutamide (MDV3100), an androgen receptor-signalling inhibitor, represents the most recent compound added to the therapeutic armamentarium for the treatment of metastatic castration-resistant prostate cancer (mCRPC) who progressed to docetaxel. The anti-tumour activity and safety of enzalutamide has been demonstrated in a phase III clinical trial, showing a benefit in overall survival, which was the primary endpoint. There are no head-to-head studies comparing the different treatment options in this subset of patients. In this article, most relevant data published in the literature have been reviewed, with special attention to the therapeutic alternatives currently available for postdocexatel mCRPC patients, emphasising the mechanisms of action of the different drugs, efficacy and quality of life-related aspects.
Keywords
Enzalutamide
Metastatic castration-resistant prostate cancer
Abiraterone
Cabazitaxel
Docetaxel
Metastatic castration-resistant prostate cancer
Abiraterone
Cabazitaxel
Docetaxel
Editor version
Rights
Atribución-NoComercial-SinDerivadas 3.0 España
ISSN
0305-7372